Treatment

Neladalkib (NVL-655) has shown strong results in patients with ALK-positive solid tumors, according to new data from the phase 1/2 ALKOVE-1 study. The drug achieved a 44% overall response rate among 34 patients, including 69% in those who had never received an ALK inhibitor and 29% in those previously treated with one. Responses appeared quickly, […]

The phase 3 VIKTORIA-1 trial showed that treatment regimens including gedatolisib significantly improved outcomes for patients with hormone receptor–positive, HER2-negative, and PIK3CA wild-type metastatic breast cancer that had progressed after CDK4/6 inhibitor therapy. Patients who received the triplet regimen (gedatolisib, palbociclib, and fulvestrant) had a median progression-free survival (PFS) of 9.3 months compared to 2.0

The final results of the Phase 3 COMPASSION-15 trial confirmed that cadonilimab, a bispecific PD-1/CTLA-4 antibody, combined with XELOX chemotherapy offers a significant long-term survival benefit for patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma compared to XELOX alone. After a median follow-up of 33.9 months, patients treated with cadonilimab plus XELOX achieved a

Researchers found that adding the targeted drug niraparib to standard treatment (abiraterone acetate and prednisone) significantly slows the progression of advanced prostate cancer in men with specific DNA repair gene mutations. The trial included 696 men whose cancer had spread and who carried Homologous Recombination Repair (HRR) gene mutations, such as BRCA1 or BRCA2. The combination therapy reduced

Izalontamab brengitecan (iza-bren; BL-B01D1), a first-in-class bispecific antibody-drug conjugate, showed significantly better and more durable outcomes than chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who had already undergone multiple treatments. In the Phase 3 BL-B01D1-301 trial involving 386 patients who had received at least two prior therapies, including platinum-based chemotherapy and a

A major international clinical trial showed that adding the drug enzalutamide to standard hormone therapy can cut the risk of death by over 40% in men whose prostate cancer returns after initial surgery or radiation. This combination therapy was tested on over 1,000 men with high-risk recurrent prostate cancer—meaning their PSA levels (a marker for the disease) were rising

Researchers have found that triple-negative breast cancer (TNBC) depends heavily on lipids—fatty acids in the body—for its growth, linking obesity to more aggressive tumor development. In preclinical mouse models, excess lipids accelerated tumor growth, while reducing lipid levels slowed it significantly. Lipids appear to act as “building blocks” that fuel rapid cancer cell proliferation. These

The phase 3 POTOMAC trial found that combining durvalumab (Imfinzi) with BCG induction and maintenance therapy significantly improved outcomes for patients with BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC). Patients receiving durvalumab with BCG induction and maintenance experienced a 32% reduction in the risk of disease-free survival (DFS) events (HR 0.68; P=0.0154), with benefits observed early and sustained throughout follow-up.

A phase 2 study presented at the 2025 ESMO Congress compared lenvatinib plus everolimus with cabozantinib in patients with metastatic clear cell renal cell carcinoma whose disease progressed after PD-1 immunotherapy. The study included 86 patients, most of whom had previously received nivolumab or ipilimumab. The combination of lenvatinib and everolimus significantly improved progression-free survival,

A phase 2 study published in Nature Communications (NCT04404088) showed that the frontline, chemotherapy-free combination of acalabrutinib (Calquence), lenalidomide (Revlimid), and rituximab (Rituxan) was both safe and effective for patients with advanced-stage, high-tumor-burden follicular lymphoma. Among 24 patients with a median follow-up of 43 months, the best complete response rate reached 92% after just six treatment